Immutep Receives FDA Fast Track Designation for Efti for First Line Non-Small Cell Lung Cancer
Posted: 5 October Fast Track designation has been granted by the US FDA for efti in combination with pembrolizumab in 1st line non-small cell lung cancer • Based on the encouraging Phase II clinical data for PD-L1 all-comers…
Optiscan Featured in Health Leader TV 2022
Posted: 4 October Part of the Australasian College of Health Service Management (ACHSM), Health Leader TV is a leading and trusted source of health service management information across the Australasian region. They provide best practice information, cutting-edge research…
Aculeus Therapeutics announces IND-enabling studies to advance lead program ACU-0943 towards clinical trials
Posted: 3 October Aculeus Therapeutics is a life sciences company focused on discovering and developing novel immunotherapies to treat a range of serious diseases. Today, Aculeus announced that it has initiated Investigational New Drug, or IND-enabling, studies for…
New $2.5m genomics project boosts precision medicine
Posted: 27 September The funding from the Medical Research Future Fund (MRFF) Genomics Health Futures Mission will support research to harness the full potential of genomic data to improve diagnosis and inform clinical care for all patients who…
Cartherics-led Consortium Receives $5.4M Federal Funding for Cellular Immunotherapy Research into Ovarian and Gastric Cancers
Posted: 27 September Cartherics, a biotechnology company developing immune cell therapies for the treatment of cancer, together within partner institutions, has received $5.4M Medical Research Futures Fund (MRFF) grant to develop a new approach to enhance cancer therapy…
Immutep Receives A$2.7 million R&D Tax Incentive from French Government
Posted: 26 September Immutep Limited, a biotechnology company developing novel LAG-3 related immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce it has received a A$2,693,046 research and development (R&D) tax incentive payment in cash from…
4DMedical formalises relationship with the University of Melbourne
Posted: 14 September The longstanding relationship between 4DMedcial and its primary research and academic partner, the University of Melbourne, has been formalised through signing of a Memorandum of Understanding (MoU). The two organisations collaborate in a number of…
Nutromics raises US$14 million for its ground-breaking wearable diagnostic platform
Posted: 8 September 2022 Melbourne, Australia & San Diego, USA: Global MedTech start-up Nutromics has raised an additional US $14 million for its wearable diagnostic platform. This transformative funding is key to Nutromics’ continued expansion across Australia and…
Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma
Posted: 6 September 2022 Expansion of the efti clinical development pipeline with a new Phase II setting Efti Phase II trial awarded €1.5M (~A$2.2M) in funding as part of the Polish Medical Research Agency program funded by the…
Luina Bio Acquisition Announcement
Posted: 1 September 2022 Dr. Glenn Haifer and Ampersand Capital Partners Acquire Australian Biologics CDMO Luina Bio, Rebranding Company as AcuraBio Brisbane, Australia – 31 August 2022 – AcuraBio (formerly Luina Bio), a leading Australian biopharmaceutical CDMO, has been…
Cloud Based Computing Services – What are the risk management and legal issues for users? – Stephens Lawyers & Consultants
Posted: 30 August 2022 Cloud services can be enablers for a company’s digital transformation. However, understanding the risks and legal issues associated with using cloud services is critical for risk management and protection of an organisation’s data and IP and to…
New Research Grant For Deoxymabs in Metastatic Breast Cancer (Patrys)
Posted: 26 August 2022 Today Patrys announced that the Olivia Newton-John Cancer Research Institute (ONJCRI) has been awarded a $100,000 Victorian State Government Victorian Medical Research Acceleration Fund (VMRAF) grant to support its research investigating the potential for PAT-DX1…
